Explanipedia

Pharmacokinetics of Sofosbuvir and Velpatasvir for Hepatitis C Treatment in Pregnancy Open

Michelle Giles, Alexandra Dunbar, Sushena Krishnaswamy, Joe Sasadeusz, Joanne Said , et al. · 2025

Background: Pregnancy is a time when women are uniquely engaged with the healthcare system and are often motivated to participate in activities directed toward improvement of their own health and ensuring the health of their unborn child, …

Incidence and Clinical Outcomes of Multiple Viral Infections After Allogeneic Hematopoietic Cell Transplantation Open

Kar Yee Yong, Shio Yen Tio, Beatrice Sim, Joe Sasadeusz, Alex Rivalland , et al. · 2025

Background Recipients of allogeneic hematopoietic cell transplantation (alloHCT) are at risk of multiple viral infections. However, our knowledge about the clinical impact of viruses following alloHCT is predominantly focused on outcomes o…

A case of enterovirus D68-associated acute flaccid myelitis in an immunocompromised adult, Australia Open

Nathaniel Lizak, Grace Butel-Simoes, Eike Steinig, Belinda Cruse, Edrich Rodrigues , et al. · 2025

Background Acute flaccid myelitis (AFM) is a predominantly pediatric, polio-like syndrome associated with enterovirus D68. AFM in adults is rare, reported predominantly in immunocompromised hosts. Case Summary Here, we report detection of …

Kinetics and Predictors of Hepatitis B Surface Antigen (HBsAg) Loss After Commencing Hepatitis B Virus (HBV)–Active Antiretroviral Therapy in the Setting of HIV and Chronic HBV Coinfection Open

Jennifer Audsley, Anchalee Avihingsanon, Xin Li, Rosalind Edwards, Kathy Merlock Jackson , et al. · 2025

Background An effective therapeutic strategy for hepatis B virus (HBV) cure remains an urgent unmet need. We aimed to define the incidence, kinetics, and predictors of hepatitis B surface antigen (HBsAg) loss in people with HIV and HBV (PW…

Clinical characteristics and treatment of varicella zoster virus central nervous system infection in an Australian tertiary hospital Open

Connie Lam, E. H. Chen, Arthur Thevathasan, Terry Yan, Michael A. Moso , et al. · 2025

Background and Aim Varicella zoster virus (VZV) is a neurotropic herpesvirus. With improved access to molecular diagnostics, there is increasing recognition of VZV with central nervous system involvement. This study aimed to describe the d…

Compassionate access to virus-specific T cells for adoptive immunotherapy over 15 years Open

Michelle A. Neller, George Ambalathingal, Nada Hamad, Joe Sasadeusz, Rebecca Pearson , et al. · 2024

Adoptive T-cell immunotherapy holds great promise for the treatment of viral complications in immunocompromised patients resistant to standard anti-viral strategies. We present a retrospective analysis of 78 patients from 19 hospitals acro…

Outcomes of Antiviral Retreatment for Immunocompromised Hosts With Prolonged Severe Acute Respiratory Syndrome Coronavirus 2 Polymerase Chain Reaction Positivity: A Multicenter Australian Retrospective Case Series Open

Katherine Bond, Claire Dendle, S Guy, Monica A. Slavin, Olivia Smibert , et al. · 2024

Outcomes are presented for a multisite retrospective case series, describing a contemporary cohort of 22 immunocompromised patients with persistent coronavirus disease 2019 (COVID-19) polymerase chain reaction positivity who were retreated…

Compassionate access to virus-specific T cells for adoptive immunotherapy over 15 years Open

Rajiv Khanna, George Ambalathingal, Nada Hamad, Joe Sasadeusz, Rebecca Pearson , et al. · 2024

Adoptive T-cell immunotherapy holds great promise for the treatment of viral complications in immunocompromised patients resistant to standard anti-viral strategies. We present a retrospective analysis of 75 patients from 15 hospitals acro…

To B or not to B: how the hepatitis B surveillance case definition can misdirect public health actions Open

Anna Pierce, Simon Crouch, Adrian Alexander, Joe Sasadeusz, Edura Jalil , et al. · 2024

Surveillance case definitions are utilised to understand the epidemiology of communicable diseases and to inform public health actions. We report a case of hepatitis B infection that meets the case definition for newly acquired infection. …

Predictors of liver disease progression in people living with HIV-HBV co-infection on antiretroviral therapy Open

Kasha P. Singh, Anchalee Avihingsanon, Jennifer M. Zerbato, Wei Zhao, Sabine Braat , et al. · 2024

Treatment for First Cytomegalovirus Infection Post–Hematopoietic Cell Transplant in the AURORA Trial: A Multicenter, Double-Blind, Randomized, Phase 3 Trial Comparing Maribavir With Valganciclovir Open

Genovefa A. Papanicolaou, Robin K. Avery, Catherine Cordonnier, Rafael F. Duarte, Shariq Haider , et al. · 2023

Background Neutropenia may limit the use of valganciclovir treatment for cytomegalovirus (CMV) infection following hematopoietic cell transplant (HCT). A phase 2 study indicated efficacy of maribavir with fewer treatment-limiting toxicitie…

Hepatitis C virus transmission between eight high-income countries among men who have sex with men: a whole-genome analysis Open

Jelle Koopsen, Gail Matthews, Juergen Rockstroh, Tanya Applegate, Sanjay Bhagani , et al. · 2023

National Institutes of Health and Dr. C.J. Vaillant Fonds.

Issue Information Open

M. Wicks, Elizabeth Barr, Louise Maple‐Brown, Sujita W. Narayan, Fady Gad , et al. · 2023

Survey of treatment practices for immunocompromised patients with COVID‐19 in Australasia Open

Michael A. Moso, Joe Sasadeusz, C. Orla Morrissey, Katherine Bond, Stephen Guy , et al. · 2023

Coronavirus disease 2019 (COVID‐19) in immunocompromised patients can lead to severe and prolonged illness. Data are limited with regard to management of COVID‐19 in this setting, particularly in persistent or recrudescent infection. The a…

Successful Implementation of an Increased Viral Risk Donor Waiting List for Preconsented Kidney Transplant Candidates in Victoria, Australia Open

Darren Lee, Indra Gramnea, Nina Seng, Meaghan Bruns, Fiona Hudson , et al. · 2021

Background. Increased viral risk donors (IVRDs) with increased risk behaviors for blood-borne virus infection and negative nucleic acid testing have a low absolute risk of “window period” infection. Utilization and allocation of IVRD organ…

Sofosbuvir/velpatasvir for 12 vs. 6 weeks for the treatment of recently acquired hepatitis C infection Open

Gail Matthews, Sanjay Bhagani, Marc van der Valk, Juergen Rockstroh, Jordan J. Feld , et al. · 2021

Corrigendum to : Therapeutics for COVID-19: established and in development Open

Kasha P. Singh, Joe Sasadeusz, Sharon R. Lewin, Jennifer Audsley · 2021

COVID-19, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was first recognised in late 2019, with over 30 000 000 cases and over 1 000 000 deaths reported by the end of September 2020. SARS-CoV-2 infection is usually…

Therapeutics for COVID-19: established and in development Open

Kasha P. Singh, Joe Sasadeusz, Sharon R. Lewin, Jennifer Audsley · 2020

COVID-19, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was first recognised in late 2019, with over 30 000 000 cases and over 1 000 000 deaths reported by the end of September 2020. SARS-CoV-2 infection is usually…

Hepatitis B related dilemmas in the renal unit Open

S. Holt, Stephen Locarnini, Joe Sasadeusz · 2020

Testing for hepatitis B in dialysis patients is routine, but newer and more sensitive detection methods mean that there is sometimes confusion around viral loads and occult infection. There are frequently difficult choices surrounding isol…

Increased risk of cervical dysplasia in females with autoimmune conditions—Results from an Australia database linkage study Open

Emma Foster, Michael J. Malloy, Vilija Jokubaitis, C. David Wrede, Helmut Butzkueven , et al. · 2020

Females with SLE/MCTD or HIV have increased rates of high-grade cervical abnormalities. The increased low-grade dysplasia rate seen in most females with AICs is consistent with increased HPV infection. These findings support expansion of c…

Review article: prevention, diagnosis and management of COVID‐19 in the IBD patient Open

Aysha Al‐Ani, Ralley Prentice, Clarissa Rentsch, Doug Johnson, Zaid Ardalan , et al. · 2020

Summary Background The current COVID‐19 pandemic, caused by SARS‐CoV‐2, has emerged as a public health emergency. All nations are seriously challenged as the virus spreads rapidly across the globe with no regard for borders. The primary ma…

The QuantiFERON Monitor® assay is predictive of infection post allogeneic hematopoietic cell transplantation Open

Abby Douglas, Lijia Yu, Vijaya Sundararajan, Jeff Szer, David Ritchie , et al. · 2020

Introduction Following allogeneic hematopoietic stem cell transplantation (alloHCT), excessive immunosuppression can be complicated by infection, while inadequate immunosuppression can result in graft‐vs‐host disease (GVHD). An accurate me…

A gathering storm Open

Nitin Kapoor, Jennifer Audsley, Priscilla Rupali, Joe Sasadeusz, Thomas V. Paul , et al. · 2019

: Despite the decreasing total incidence of liver-related deaths, liver disease remains one of the major non-AIDS causes of morbidity and mortality amongst people living with HIV, and a significant proportion of liver disease in these indi…

Efficacy and Safety of Glecaprevir/Pibrentasvir in Patients Co-infected With Hepatitis C Virus and Human Immunodeficiency Virus-1: the EXPEDITION-2 Study Open

Maldonado Vázquez, JK Rockstroh, Karine Lacombe, Chloe Orkin, Annie Luetkemeyer , et al. · 2018

Background: Pangenotypic, once-daily glecaprevir (identified by AbbVie and Enanta) co-formulated with pibrentasvir (G/P) has demonstrated high rates of sustained virologic response (HCV RNA < lower limit of quantification [LLOQ]) at 12 wee…

IDDF2018-ABS-0067 Efficacy and safety of glecaprevir/pibrentasvir in patients with hcv genotype 5 or 6 infection: the endurance-5, 6 study Open

Tarik Asselah, Tram T. Tran, Katia Alves, Tuan Nguyen, Florence Wong , et al. · 2018

Background The pangenotypic direct-acting antivirals (DAAs) glecaprevir (developed by AbbVie and Enanta)/pibrentasvir (G/P) are approved to treat chronic HCV genotype (GT)1–6 infection. In Phase 2 and 3 studies, G/P achieved high SVR12 rat…

HBV, HCV, and HBV/HCV co‐infection among HIV‐positive patients in Hunan province, China: Regimen selection, hepatotoxicity, and antiretroviral therapy outcome Open

Shu Su, Christopher K. Fairley, Joe Sasadeusz, Jianmei He, Xiuqing Wei , et al. · 2017

Co‐infection with hepatitis B (HBV) and C (HCV) is common among people living with HIV (PLHIV). This study investigates the impacts of hepatitis co‐infection on antiretroviral therapy (ART) outcomes and hepatotoxicity in PLHIV. The cohort …

O5 Hepatitis C elimination in HIV/HCV co-infection through HCV treatment in primary care is feasible and highly effective Open

Joseph Doyle, Anna L. Bowring, Julia C. Cutts, Janine Roney, David Iser , et al. · 2017

O14 Community prescribing of hepatitis C treatment: a mentorship and capacity building model to increase treatment uptake by targeted populations Open

Sally Watkinson, Lisa Accadia, Lauren Coelli, G. Bartlett, Thomas Schulz , et al. · 2017

P65 Nurse-led hepatitis C treatment models in drug and alcohol services can support, treatment uptake, healthcare engagement and community prescribing Open

Sally Watkinson, Sandhya Mujumdar, Benny Monheit, Joe Sasadeusz · 2017

HIV-hepatitis B virus coinfection Open

Kasha P. Singh, Megan Crane, Jennifer Audsley, Anchalee Avihingsanon, Joe Sasadeusz , et al. · 2017

: HIV infection has a significant impact on the natural history of chronic hepatitis B virus (HBV) infection, with increased levels of HBV DNA, accelerated progression of liver disease and increased liver-associated mortality compared with…

Joe Sasadeusz YOU? Author Swipe